Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 4/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 7/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | TYK2 | P29597 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 3/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22676924 | 1.00 | ITK (0.49) | ITKFGFR1FGFR4EGFRBTK | |
| SCHEMBL25231711 | 0.91 | BTK (0.56) | ITKFGFR1EGFRBTKJAK3 | |
| SCHEMBL22676329 | 0.91 | BTK (0.56) | ITKFGFR1EGFRBTKJAK3 | |
| SCHEMBL30303279 | 0.91 | BTK (0.56) | ITKFGFR1EGFRBTKJAK3 | |
| SCHEMBL22676206 | 0.89 | ITK (0.60) | ITKFGFR1FGFR4BTKFGFR2 | |
| SCHEMBL30303367 | 0.89 | BTK (0.60) | ITKFGFR1EGFRBTKJAK3 | |
| SCHEMBL26084486 | 0.89 | BTK (0.60) | ITKFGFR1EGFRBTKJAK3 | |
| SCHEMBL22677406 | 0.89 | BTK (0.60) | ITKFGFR1EGFRBTKJAK3 | |
| SCHEMBL22676275 | 0.89 | ITK (0.51) | ITKFGFR1FGFR4EGFRBTK | |
| SCHEMBL22675813 | 0.89 | ITK (0.49) | ITKFGFR1FGFR4EGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
| WO-2020231990-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | ITK 1273/4885FGFR1 3/4885FGFR4 4/4885 |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | FGFR3, FGFR2, FGFR1 | ITK 1273/4885FGFR1 3/4885FGFR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.